Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83(5):584-94
   PubMed Web of Science ®Google Scholar
• Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999;5(6):1319-23
   PubMed Web of Science ®Google Scholar
• Jansen RL, Slingerland R, Goey SH, et al. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother. (1991) 1992;12(1):70-3
   PubMed Web of Science ®Google Scholar
• Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3(1):49-57. discussion 58
   PubMedGoogle Scholar
• Giaccone G, Bazhenova L, Nemunaitis J, et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC) [abstract 2]. European Cancer Congress Abstracts; 2013
   Google Scholar
• Butts C, Socinski M, Mitchell P, et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 2013;31(Suppl):abstract 7500
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin. Available from: http://clinicaltrials.gov/show/NCT01285609
   Google Scholar
• Trial in extensive-disease small cell lung cancer (ED-SCLC) subjects comparing ipilimumab plus etoposide and platinum therapy to etoposide and platinum therapy alone. Available from: http://trialsunited.com/studies/NCT01450761
   Google Scholar
• Small cell lung cancer trial with ipilimumab in limited disease (STIMULI). Available from: http://clinicaltrials.gov/show/NCT02046733
   Google Scholar
• Available from: www.clinicaltrials.gov Last accessed 8 July 2014
   Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117(5):1137-46
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002;188:9-21
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331(6013):44-9
   PubMed Web of Science ®Google Scholar
• Derniame S, Vignaud JM, Faure GC, Bene MC. Alteration of the immunological synapse in lung cancer: a microenvironmental approach. Clin Exp Immunol 2008;154(1):48-55
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81
   PubMed Web of Science ®Google Scholar
• Karanikas V, Zamanakou M, Kerenidi T, et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 2007;6(8):1258-62
   PubMed Web of Science ®Google Scholar
• Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482(7385):400-4
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480(7378):480-9
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64
   PubMed Web of Science ®Google Scholar
• Schneider T, Hoffmann H, Dienemann H, et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol 2011;6(7):1162-8
   PubMed Web of Science ®Google Scholar
• Smith C, Chang MY, Parker KH, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012;2(8):722-35
   PubMed Web of Science ®Google Scholar
• Sterlacci W, Wolf D, Savic S, et al. High transforming growth factor beta expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 2012;43(3):339-49
   PubMed Web of Science ®Google Scholar
• Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14(16):5220-7
   PubMed Web of Science ®Google Scholar
• Miotto D, Lo Cascio N, Stendardo M, et al. CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer. Lung Cancer 2010;69(3):355-60
   PubMed Web of Science ®Google Scholar
• Zhuang X, Xia X, Wang C, et al. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010;18(1):24-8
   PubMedGoogle Scholar
• Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26(27):4410-17
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94(2):275-80
   PubMed Web of Science ®Google Scholar
• Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008;113(6):1387-95
   PubMed Web of Science ®Google Scholar
• Al-Shibli K, Al-Saad S, Donnem T, et al. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 2009;55(3):301-12
   PubMed Web of Science ®Google Scholar
• Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003;9(2):729-37
   PubMed Web of Science ®Google Scholar
• Dai F, Liu L, Che G, et al. The number and microlocalization of tumor-associated immune cells are associated with patient’s survival time in non-small cell lung cancer. BMC Cancer 2010;10:220
   PubMed Web of Science ®Google Scholar
• Eerola AK, Soini Y, Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 2000;6(5):1875-81
   PubMed Web of Science ®Google Scholar
• Wang W, Hodkinson P, McLaren F, et al. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int J Cancer 2012;131(6):E928-37
   PubMed Web of Science ®Google Scholar
• Usó M, Jantus-Lewintre E, Sirera R, et al. Analysis of the prognostic impact of Treg-related genes in tumor and stroma in resectable NSCLC. J Clin Oncol 2013;31(Suppl):abstract 11073
   Google Scholar
• Kadota K, Nitadori JI, Adusumilli PS. Prognostic value of the immune microenvironment in lung adenocarcinoma. Oncoimmunology 2013;2(5):e24036
   PubMed Web of Science ®Google Scholar
• Shimizu K, Nakata M, Hirami Y, et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5(5):585-90
   PubMed Web of Science ®Google Scholar
• Koyama K, Kagamu H, Miura S, et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008;14(21):6770-9
   PubMed Web of Science ®Google Scholar
• Erfani N, Mehrabadi SM, Ghayumi MA, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2012;77(2):306-11
   PubMed Web of Science ®Google Scholar
• Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72(9):2162-71
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012;72(13):3125-30
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6(4):295-307
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009;206(8):1717-25
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3(5):541-7
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270(5238):985-8
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24(1):75-83
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30(17):2046-54
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Heo DS, Park K, et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(Suppl):abstract 8071
   Google Scholar
• Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011;71(16):5393-9
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793-800
   PubMed Web of Science ®Google Scholar
• Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 2011;84(4):409-21
   PubMedGoogle Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24(2):207-12
   PubMed Web of Science ®Google Scholar
• Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94(1):107-16
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293-7
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198(6):851-62
   PubMed Web of Science ®Google Scholar
• Hodi F, Topalian SL, Brahmer JR, et al. Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract 880]. European Cancer Congress Meeting Abstracts; 2013
   Google Scholar
• Brahmer JR, Horn L, Antonia SJ, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial [abstract MO18.03]. World Conference on Lung Cancer Meeting Abstracts; 2013
   Google Scholar
• Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. J Clin Oncol 2014;32(Suppl):abstract 8112
   Google Scholar
• Gettinger SN, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 2014;32(Suppl):abstract 8024
   Google Scholar
• Study of nivolumab (BMS-936558) in subjects with advanced or metastatic squamous cell non-small cell lung cancer who have received at least two prior systemic regimens (CheckMate 063). Available from: http://clinicaltrials.gov/show/NCT01721759
   Google Scholar
• Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (CheckMate 017). Available from: http://clinicaltrials.gov/show/NCT01642004
   Google Scholar
• SCCA clinical studies: lung cancer. Available from: http://www.seattlecca.org/clinical-trials/lungcancer-NCT01673867
   Google Scholar
• An open-label, randomized, phase 3 trial of nivolumab versus investigator’s choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (CheckMate 026). Available from: http://clinicaltrials.gov/show/NCT02041533
   Google Scholar
• Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(Suppl):abstract 8020
   Google Scholar
• Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(Suppl):abstract 8007
   Google Scholar
• Study of two doses of mk-3475 (pembrolizumab) versus docetaxel in previously-treated participants with non-small cell lung cancer (MK-3475-010/KEYNOTE-010). Available from: http://therapy.collabrx.com/lung/trial/NCT01905657
   Google Scholar
• Horn L, Herbst RS, Spigel D, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1) [abstract MO18.01]. World Conference on Lung Cancer Meeting Abstracts; 2013
   Google Scholar
• A phase 2 study of MPDL3280A (an engineered Anti-PDL1 antibody) in patients With PD-L1 positive locally advanced or metastatic non-small cell lung cancer - “FIR”. Available from: http://clinicaltrials.gov/show/NCT01846416
   Google Scholar
• A randomized phase 2 study of MPDL3280A (an engineered Anti-PDL1 antibody) compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy - “POPLAR”. Available from: http://clinicaltrials.gov/show/NCT01903993
   Google Scholar
• A randomized phase 3 study of MPDL3280A (an engineered Anti-PDL1 antibody) compared to docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy - “OAK”. Available from: http://clinicaltrials.gov/show/NCT02008227
   Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65
   PubMed Web of Science ®Google Scholar
• A phase 1 study to evaluate MEDI4736. Available from: http://clinicaltrials.gov/show/NCT01693562
   Google Scholar
• Brahmer JR, Rizvi NA, Lutzky J, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol 2014;32(Suppl):abstract 8021
   Google Scholar
• Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117(11):3383-92
   PubMed Web of Science ®Google Scholar
• Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011;15(1):91-101
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72(4):917-27
   PubMed Web of Science ®Google Scholar
• Safety study of anti-LAG-3 with and without anti-PD-1 in the treatment of solid tumors. Available from: http://clinicaltrials.gov/show/NCT01968109
   Google Scholar
• Safety study of BMS-986015 (Anti-KIR) in combination with ipilimumab in subjects with selected advanced tumor. Available from: http://clinicaltrials.gov/show/NCT01750580
   Google Scholar
• A phase I study of an anti-KIR antibody in combination with an anti-PD1 antibody in patients with advanced solid tumors. Available from: http://clinicaltrials.gov/show/NCT01714739
   Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122-33
   PubMed Web of Science ®Google Scholar
• A phase 1/2, open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors. Available from: http://clinicaltrials.gov/show/NCT01928394
   Google Scholar
• Antonia SJ, Gettinger SN, Chow LQM, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol 2014;32(Suppl):abstract 8023
   Google Scholar
• Study of nivolumab (BMS-936558) in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, carboplatin/paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB/IV non-small cell lung cancer (NSCLC) (CheckMate 012). Available from: http://clinicaltrials.gov/show/NCT01454102
   Google Scholar
• A study of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with lung cancer (MK-3475-021/KEYNOTE-021). Available from: http://clinicaltrials.gov/show/NCT02039674
   Google Scholar
• Pinder MC, Rizvi NA, Goldberg SB, et al. A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in subjects with advanced non–small cell lung cancer. J Clin Oncol 2014:32(Suppl):abstract e19137^
   Google Scholar
• Segal NH, Hodi FS, Sanborn RE, et al. A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. J Clin Oncol 2014;32(Suppl):abstract TPS3115
   Google Scholar
• Hodge JW, Ardiani A, Farsaci B, et al. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 2012;39(3):323-39
   PubMed Web of Science ®Google Scholar
• Drake CG. Combination immunotherapy approaches. Ann Oncol 2012;23(Suppl 8):viii41-6
   PubMed Web of Science ®Google Scholar
• Ménard C, Martin F, Apetoh L, et al. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008;57(11):1579-87
   PubMed Web of Science ®Google Scholar
• Hannani D, Sistigu A, Kepp O, et al. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 2011;17(5):351-8
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol 2013;25(2):291-29
   PubMed Web of Science ®Google Scholar
• Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther 2009;11(1):37-42
   PubMedGoogle Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013;105(4):256-65
   PubMed Web of Science ®Google Scholar
• Bramhall RJ, Mahady K, Peach AH. Spontaneous regression of metastatic melanoma - clinical evidence of the abscopal effect. Eur J Surg Oncol 2014;40(1):34-41
   PubMed Web of Science ®Google Scholar
• Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013;1(6):365-72
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Chen DS, Knox SJ. Abscopal effect in a patient with melanoma. N Engl J Med 2012;366:2035-6
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366(10):925-31
   PubMed Web of Science ®Google Scholar
• Reck M, Gonzalez-Mella P, Ahn M-J, et al. Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology. J Clin Oncol 2013;31(Suppl):abstract TPS8117
   Google Scholar
• Rizvi N, Antonia SJ, Chow LQM, et al. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013;31(Suppl):abstract 8072
   Google Scholar
• Antonia SJ, Brahmer JR, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(Suppl):abstract 8113
   Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12(4):237-51
   PubMed Web of Science ®Google Scholar
• Hodi F, Friedlander PA, Atkins MB, et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2011;29(Suppl):abstract 8511
   Google Scholar
• Rizvi NA, Chow LQM, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol 2014;32(Suppl):abstract 8022
   Google Scholar
• Chow LQ. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book 2013
   PubMedGoogle Scholar
• Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010;37(5):499-507
   PubMed Web of Science ®Google Scholar
• Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013;18(6):733-43
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30(21):2691-7
   PubMed Web of Science ®Google Scholar
• Topalian S, Sznol M, Brahmer JR, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. J Clin Oncol 2013;31(Suppl):abstract 3002
   Google Scholar
• Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. Clin Endocrinol Metab 2013;98(4):1361-75
   Google Scholar
• Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9
   PubMedGoogle Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
   PubMed Web of Science ®Google Scholar
• Daud AI, Hamid O, Ribas A, et al. Antitumor activity of the anti-PD-1 monoclonal antibody pembrolizumab in melanoma (MEL): correlation of tumor PD-L1 expression with outcome [abstract CT104]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5-9 April 2014; San Diego, CA. Philadelphia (PA). 2014
   Google Scholar
• Antonia S, Grosso JF, Horak CE, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer (NSCLC) treated with nivolumab (Anti-PD-1; BMS-936558; ONO-4538). [abstract P2.11-035]. World Conference on Lung Cancer Meeting Abstracts (2013); 2013
   Google Scholar
• A phase 1b study of MDX-1106 in subjects with advanced or recurrent malignancies (MDX1106-03). Available from: http://clinicaltrials.gov/show/NCT00730639
   Google Scholar
• McDermott D, Haanen J, Chen TT, et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 2013;24(10):2694-8
   PubMed Web of Science ®Google Scholar
• Safety and efficacy trial of ipilimumab versus pemetrexed in non-squamous non-small cell lung cancer. Available from: http://clinicaltrials.gov/show/NCT01471197
   Google Scholar
• A safety trial of nivolumab (BMS-936558) in subjects with advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior systemic regimen (CheckMate 153). Available from: http://clinicaltrials.gov/show/NCT02066636
   Google Scholar
• Study of pembrolizumab (MK-3475) in participants with progressive locally advanced or metastatic carcinoma, melanoma, or non-small cell lung carcinoma (P07990/MK-3475-001/KEYNOTE-001). Available from: http://clinicaltrials.gov/show/NCT01295827
   Google Scholar
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025). Available from: http://clinicaltrials.gov/show/NCT02007070
   Google Scholar
• MK-3475 in melanoma and NSCLC patients with brain metastases. Available from: http://clinicaltrials.gov/show/NCT02085070
   Google Scholar
• Study of pembrolizumab (MK-3475) compared to platinum-based chemotherapies in participants with metastatic non-small cell lung cancer (MK-3475-024/KEYNOTE-024). Available from: http://clinicaltrials.gov/show/NCT02142738
   Google Scholar
• A PHASE 2 study of MPDL3280A (an engineered Anti-PDL1 antibody) in patients With PD-L1 positive locally advanced or metastatic non-small cell lung cancer - “BIRCH”. Available from: http://clinicaltrials.gov/show/NCT02031458
   Google Scholar
• A global study to assess the effects of MEDI4736 in patients with locally advanced or metastatic non small cell lung cancer (ATLANTIC). Available from: http://clinicaltrials.gov/show/NCT02087423
   Google Scholar
• A global study to assess the effects of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer (PACIFIC). Available from: http://clinicaltrials.gov/show/NCT02125461
   Google Scholar
• A phase 1b study of MEDI4736 in combination with tremelimumab in subjects with advanced non-small cell lung cancer (D4190C00006). Available from: http://clinicaltrials.gov/show/NCT02000947
   Google Scholar
• Japanese study of ipilimumab administered in combination with Paclitaxel/Carboplatin in patients with nonsmall-cell lung cancer. Available from: http://clinicaltrials.gov/show/NCT01165216
   Google Scholar
• Evaluation of circulating t cells and tumor infiltrating lymphocytes (TILs) during / after pre-surgery chemotherapy in non-small cell lung cancer (NSCLC) (TOP1201 IPI). Available from: http://clinicaltrials.gov/show/NCT01820754
   Google Scholar
• Study of pembrolizumab (MK-3475) monotherapy in participants with advanced solid tumors and pembrolizumab combination therapy in participants with advanced non-small cell lung cancer (MK-3475-011/KEYNOTE-011). Available from: http://clinicaltrials.gov/show/NCT01840579
   Google Scholar
• Ipilimumab plus targeted inhibitor (erlotinib or crizotinib) for EGFR or ALK mutated stage IV non-small cell lung cancer: phase Ib with expansion cohorts. Available from: http://clinicaltrials.gov/show/NCT01998126
   Google Scholar
• A phase 1b study of MPDL3280A (an engineered Anti-PDL1 antibody) in combination with tarceva in patients with non-small cell lung cancer. Available from: http://clinicaltrials.gov/show/NCT02013219
   Google Scholar
• MEDI4736 (Anti PD-L1) combined with gefitinib in subjects with non-Small cell lung cancer(NSCLC). Available from: http://clinicaltrials.gov/show/NCT02088112
   Google Scholar
• AZD9291 in combination with ascending doses of novel therapeutics. Available from: http://clinicaltrials.gov/show/NCT02143466
   Google Scholar
• Tolerability and efficacy of tremelimumab in combination with gefitinib in NSCLC patients (GEFTREM). Available from: http://clinicaltrials.gov/show/NCT02040064
   Google Scholar
• A Phase 1/2 study exploring the safety, tolerability, and efficacy of MK-3475 in combination with INCB024360 in subjects with selected solid tumors and advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037). Available from: http://clinicaltrials.gov/show/NCT02178722
   Google Scholar
• Immune-modulated study of selected small molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st immune-mediated therapy (IMT; Tremelimumab) with a sequential switch to a 2nd IMT (MEDI4736) in patients with locally advanced or metastatic non-small-cell lung cancer. Available from: http://clinicaltrials.gov/show/NCT02179671
   Google Scholar